Results 61 to 70 of about 9,664,759 (367)

Sex and ethnicity in early‐onset Alzheimer's disease biomarkers and global function

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
INTRODUCTION Early‐onset Alzheimer's disease (EOAD) may have distinct biomarker and clinical features from late‐onset AD (LOAD). EOAD is understudied in ethnically heterogeneous populations. METHODS We studied EOAD (N = 44, age 64.7 ± 5.5, 55% female, 52%
Breton M. Asken, Wei‐En Wang, Franchesca Arias, Shellie‐Anne Levy, Warren W. Barker, Monica Rosselli, Rosie Curiel Cid, Michael Marsiske, Melissa J. Armstrong, David E. Vaillancourt, David A. Loewenstein, Glenn E. Smith, Ranjan Duara   +12 more
doaj   +1 more source

Forecasting the progression of Alzheimer's disease using neural networks and a novel preprocessing algorithm

Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2019
Introduction There is a 99.6% failure rate of clinical trials for drugs to treat Alzheimer's disease, likely because Alzheimer's disease (AD) patients cannot be easily identified at early stages. This study investigated machine learning approaches to use
Jack Albright, Alzheimer's Disease Neuroimaging Initiative   +1 more
doaj   +1 more source

Cross‐sectional and longitudinal evaluation of plasma glial fibrillary acidic protein to detect and predict clinical syndromes of Alzheimer's disease

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, 2023
Introduction This study examined plasma glial fibrillary acidic protein (GFAP) as a biomarker of cognitive impairment due to Alzheimer's disease (AD) with and against plasma neurofilament light chain (NfL), and phosphorylated tau (p‐tau)181+231.
Madeline Ally, Michael A. Sugarman, Henrik Zetterberg, Kaj Blennow, Nicholas J. Ashton, Thomas K. Karikari, Hugo J. Aparicio, Brandon Frank, Yorghos Tripodis, Brett Martin, Joseph N. Palmisano, Eric G. Steinberg, Irene Simkin, Lindsay A. Farrer, Gyungah R. Jun, Katherine W. Turk, Andrew E. Budson, Maureen K. O'Connor, Rhoda Au, Lee E. Goldstein, Neil W. Kowall, Ronald Killiany, Robert A. Stern, Thor D. Stein, Ann C. McKee, Wei Qiao Qiu, Jesse Mez, Michael L. Alosco   +27 more
doaj   +1 more source

Prediction of Cognitive Decline in Healthy Older Adults using fMRI [PDF]

, 2010
Few studies have examined the extent to which structural and functional MRI, alone and in combination with genetic biomarkers, can predict future cognitive decline in asymptomatic elders.
Antuono, Piero, Butts, Alissa, Durgerian, Sally, Guidotti, Leslie, Hantke, Nathan, Lancaster, Melissa A., Nielson, Kristy A., Rao, Stephen M., Seidenberg, Michael, Smith, J Carson, Woodard, John L., Zhang, Qi   +11 more
core   +2 more sources

Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020–2060)

Alzheimer's & Dementia, 2021
The estimate of people with clinical Alzheimer's disease (AD) and mild cognitive impairment provides an understanding of the disease burden.
K. Rajan, J. Weuve, L. Barnes, Elizabeth A Mcaninch, R. Wilson, Denis A. Evans   +5 more
semanticscholar   +1 more source

The epithelial barrier theory proposes a comprehensive explanation for the origins of allergic and other chronic noncommunicable diseases

FEBS Letters, EarlyView.
Exposure to common noxious agents (1), including allergens, pollutants, and micro‐nanoplastics, can cause epithelial barrier damage (2) in our body's protective linings. This may trigger an immune response to our microbiome (3). The epithelial barrier theory explains how this process can lead to chronic noncommunicable diseases (4) affecting organs ...
Can Zeyneloglu, Huseyn Babayev, Ismail Ogulur, Sena Ardicli, Yagiz Pat, Duygu Yazici, Bingjie Zhao, Lihong Chang, Xiaoqing Liu, Paolo D'Avino, Manru Li, Ceren Biçer, Fatma Hacer Kurtoğlu Babayev, Raja Dhir, Kari C. Nadeau, Marie‐Charlotte Brüggen, Mubeccel Akdis, Cezmi A. Akdis   +17 more
wiley   +1 more source

Plasma p‐tau217 concordance with amyloid PET among ethnically diverse older adults

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
INTRODUCTION Commercially available plasma p‐tau217 biomarker tests are not well studied in ethnically diverse samples. METHODS We evaluated associations between ALZPath plasma p‐tau217 and amyloid‐beta positron emission tomography (Aβ‐PET) in Hispanic ...
Breton M. Asken, Jesse C. DeSimone, Wei‐En Wang, Karen N. McFarland, Franchesca Arias, Shellie‐Anne Levy, Jacob Fiala, Idaly Velez‐Uribe, Robin P. Mayrand, Luana Okino Sawada, Christian Freytes, Michael Adeyosoye, Warren W. Barker, Elizabeth A. Crocco, Steven T. DeKosky, Malek Adjouadi, Monica Rosselli, Michael Marsiske, Melissa J. Armstrong, Glenn E. Smith, Rosie Curiel Cid, David A. Loewenstein, David E. Vaillancourt, Ranjan Duara   +23 more
doaj   +1 more source

T2 Protect AD: Achieving a rapid recruitment timeline in a multisite clinical trial for individuals with mild to moderate Alzheimer's disease

Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2022
Introduction The reporting of approaches facilitating the most efficient and timely recruitment of Alzheimer's disease (AD) patients into pharmacologic trials is fundamental to much‐needed therapeutic progress.
Aladdin H. Shadyab, Andrea Z. LaCroix, Genevieve Matthews, Daniel Bennett, Alexandre A. Shadyab, Donna Tan, Ronald G. Thomas, Jennifer Mason, Alex Lopez, Brianna Askew, Lia Donahue, Stephen Kaplita, Irfan A. Qureshi, Branko Huisa, Howard H. Feldman, for the Alzheimer's Disease Cooperative Study T2 Protect AD Study Group   +15 more
doaj   +1 more source

Automatic memory processes in normal ageing and Alzheimer’s disease [PDF]

, 2008
This study examined the contribution of automatic and controlled uses of memory to stem completion in young, middle-aged and older adults, and compared these data with a study involving patients with Alzheimer’s disease (AD) who performed the same task ...
Adam, Albert, Bäckman, Bäckman, Carlesimo, Cermak, Chiarello, Clarys, Curran, Davis, DeKosky, Deweer, Fleischman, Folstein, Fuster, Gabrieli, Graf, Habib, Hudson, Hultsch, Huppert, Jacoby, Jacoby, Jacoby, Jennings, Jermann, John M. Hudson, Knight, Koivisto, La Voie, Light, McKhann, Meiran, Mitchell, Morris, Nelson, Neumann, Partridge, Reingold, Richardson-Klavehn, Russo, Ryan, Salthouse, Schacter, Schmitter-Edgecombe, Smith, Squire, Titov, Toth, Zelazo   +49 more
core   +1 more source

Rethinking Alzheimer’s Disease [PDF]

Frontiers in Neurology, 2012
Alzheimer’s disease (AD) is a neurodegenerative disorder with insidious onset and progressive course, which prevalence increases with the age. It is characterized by neuronal degeneration and death, related to the deposition in the brain of the amyloid β1–42 peptide and the hyperphosphorylated tau protein, and initially affects brain areas, namely the ...
openaire   +4 more sources